Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is 1 to 17 years of age~* Able to provide a first-morning urine sample each day during the study~* Documented history of proteinuria associated with chronic kidney disease of any origin~* Signed consent of parent and/or legal guardian~Exclusion Criteria:~* Pregnant and/or nursing~* Requires more than 2 medications to control high blood pressure~* Has undergone major organ transplantation (e.g. heart, kidney, liver)~* Known sensitivity to losartan or other similar drugs, or any history of angioneurotic edema~* Known sensitivity to amlodipine or other calcium channel blocker~* Requires cyclosporine to treat renal disease (kidney disease)

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Losartan Double-Blind Base Study (12-weeks) (Type: EXPERIMENTAL): Normotensive participants received losartan.~Hypertensive participants received either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo).
- Amlodipine Double-Blind Base Study (12-weeks) (Type: ACTIVE_COMPARATOR): Hypertensive participants were randomized to receive either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo) for 12 weeks.
- Losartan Open-Label Extension Phase (Month 36) (Type: EXPERIMENTAL): Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
- Enalapril Open-Label Extension Phase (Month 36) (Type: ACTIVE_COMPARATOR): Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).

Based on this trial design, predict the completion outcome and termination type (if applicable).